Novel KAT6B::NUTM2B fusion oncogene in congenital acute myeloid leukemia and implications for menin inhibitor therapy [0.03%]
先天性急性髓系白血病中的新型KAT6B::NUTM2B融合癌基因及其对男恩抑制剂治疗的意义
Rebecca K Voss,Wenqing Qi,La&#x;Ron Browne et al.
Rebecca K Voss et al.
Not available.
Recovering from a therapeutic stall in higher-risk myelodysplastic syndromes: re-examining biology, backbones and study designs [0.03%]
高危骨髓增生异常综合征治疗平台期的恢复：重新审视生物学、化疗基础和研究设计
Sudhir Tauro,Ayalew Tefferi
Sudhir Tauro
Therapeutic progress in higher-risk myelodysplastic syndromes (HR-MDS) has stalled. Despite repeated attempts to improve outcomes through incremental refinements to classification systems and hypomethylating agent (HMA)-based backbones, no ...
Pre-treatment circulating microRNA signatures predict outcomes of anti-CD19 CAR T-cell therapy [0.03%]
治疗前循环小RNA标志物可预测抗CD19 CAR-T细胞疗法的疗效
Maria Naddeo,Roberta Roncarati,Francesco De Felice et al.
Maria Naddeo et al.
Not available.
Allograft inflammatory factor -1 is essential for acute monocytic leukemia infiltration [0.03%]
同种异体移植物炎症因子-1对急性单核细胞白血病浸润是必不可少的
Ai-Li Chen,Hai-Yang Hu,Doaa Alamoudi et al.
Ai-Li Chen et al.
Not available.
Long-term outcome of allogeneic hematopoietic cell transplantation for T-cell prolymphocytic leukemia - a study on behalf of the Chronic Malignancies Working Party of the EBMT [0.03%]
异基因造血干细胞移植治疗T细胞大颗粒淋巴细胞白血病的长期疗效分析——由欧洲血液及骨髓移植慢性恶性肿瘤工作组报道
Joanna Drozd-Sokolowska,Luuk Gras,Laurien G A Baaij et al.
Joanna Drozd-Sokolowska et al.
Not available.
Phase Ib/II trial of anti-CD33 monoclonal antibody BI 836858 and azacitidine in previously untreated older acute myeloid leukemia patients: Beat AML S2 sub-study results [0.03%]
抗CD33单克隆抗体BI 836858与新基霉素治疗未经治疗的急性髓系白血病患者Ib/II期临床试验：Beat AML S2子研究结果
Michael J Hochman,Amy S Ruppert,Ying Huang et al.
Michael J Hochman et al.
Not available.
Hematological theology and the limits of retrospective diagnosis: a critique of the hemophilia hypothesis in Exodus 4:24-26. Comment on: ""Bridegroom of blood" - a biblical reference to hemophilia?" [0.03%]
血细胞的神学和回溯性诊断的局限性：对《出埃及记》4:24-26中血友病假说的批判。评论文章：“新郎的血液”——《圣经》中有血友病的暗示吗？
G Shellye Horowitz
G Shellye Horowitz
Not available.
Bedaquiline amplifies proteasome inhibitor efficacy and overcomes resistance in multiple myeloma [0.03%]
苯达喹啉可增强蛋白酶体抑制剂的疗效并克服多发性骨髓瘤耐药性
Michela Cumerlato,Monica Maccagno,María Labrador et al.
Michela Cumerlato et al.
Proteasome inhibitors (PIs) are cornerstone therapies for multiple myeloma (MM), yet resistance remains a major barrier to durable responses. To identify druggable vulnerabilities that enhance PI efficacy, we performed a small-molecule chem...
Brentuximab-vedotin and bendamustine for relapsed or refractory Hodgkin lymphoma: the LYSA real-world experience [0.03%]
Brentuximab- vedotin和苯达莫司汀治疗复发或难治性霍奇金淋巴瘤：LYSA真实世界经验
Gaetan Basile,Arnaud Neuville,Delphine Martineau et al.
Gaetan Basile et al.
Classical Hodgkin lymphoma (HL) is often cured after modern first line regimen but relapsed or refractory (R/R) diseases remain a therapeutical challenge that has been addressed by little randomized clinical trials. Several combinations of ...
SQSTM1::RARA fusion in acute promyelocytic leukemia: the first case report and literature review [0.03%]
SQSTM1::RARA融合在急性早幼粒细胞白血病中的首例报道及文献综述
Xiaomei Yin,Na Li,Zhanrui Cheng et al.
Xiaomei Yin et al.
Not available.